Identification

Name
Dextromethorphan
Accession Number
DB00514  (APRD00655)
Type
Small Molecule
Groups
Approved
Description

The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity. [PubChem]

Structure
Thumb
Synonyms
  • (+)-dextromethorphan
  • D-methorphan
  • delta-Methorphan
  • Dex
  • Dextromethorfan
  • Dextromethorphan
  • Dextrométhorphane
  • Dextromethorphanum
  • Dextrometorfano
  • DM
External IDs
BA 2666
Product Ingredients
IngredientUNIICASInChI Key
Dextromethorphan hydriodide086F8ZEM777487-74-3RWSHVMCJJPXQSP-URVXVIKDSA-N
Dextromethorphan hydrobromideZ0CG3115FG125-69-9MISZALMBODQYFT-URVXVIKDSA-N
Dextromethorphan hydrobromide monohydrate9D2RTI9KYH6700-34-1STTADZBLEUMJRG-IKNOHUQMSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cough Syrup DMSyrup15 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.Not applicableNot applicableCanada
DM 7.5mg Croquable (chewable Tablet)Tablet, chewable7.5 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
12 Hour Cough ReliefSuspension30 mg/5mLOralWestern Family Foods2013-07-03Not applicableUs
12 Hour Cough ReliefSuspension30 mg/5mLOralWestern Family Foods2012-09-14Not applicableUs
7 Select Cough DMSuspension30 mg/5mLOral7 Eleven2014-09-05Not applicableUs
Adult Cough Relief DMLiquid30 mg/10mLOralSafeway2014-06-30Not applicableUs
Adult Honey WorksSyrup20 mgOralLifelab Health LlcNot applicableNot applicableCanada
Adult Long Lasting-Cough ReliefCapsule15 mg/1OralChain Drug Consortium2013-05-22Not applicableUs
Adult Tussin CoughLiquid30 mg/10mLOralWestern Family Foods1992-09-11Not applicableUs
Adult Tussin Cough GelsCapsule, gelatin coated15 mg/1OralArmy + Air Force Exchange Service2006-04-24Not applicableUs
Adult Wal Tussin Cough Long ActingSolution30 mg/10mLOralWalgreen2004-09-03Not applicableUs
Balminil DMSyrup3 mgOralTeva1979-12-31Not applicableCanada
International/Other Brands
Benylin DM (McNeil) / Romilar (Bayer) / Triaminic (Novartis) / Vicks Formula 44 (Procter & Gamble)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Day Time ReliefDextromethorphan hydrobromide (10 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOral7 Eleven2014-04-22Not applicableUs
7 Select Day Time ReliefDextromethorphan hydrobromide (10 mg/15mL) + Acetaminophen (325 mg/15mL) + Phenylephrine hydrochloride (5 mg/15mL)SolutionOral7 Eleven2014-08-05Not applicableUs
7 Select Night Time ReliefDextromethorphan hydrobromide (15 mg/1) + Acetaminophen (325 mg/1) + Doxylamine succinate (6.25 mg/1)Capsule, gelatin coatedOral7 Eleven2014-04-17Not applicableUs
7 Select Night Time ReliefDextromethorphan hydrobromide (30 mg/30mL) + Acetaminophen (650 mg/30mL) + Doxylamine succinate (12.5 mg/30mL)SolutionOral7 Eleven2014-08-05Not applicableUs
7 select Tussin DMDextromethorphan hydrobromide (20 mg/10mL) + Guaifenesin (200 mg/10mL)SolutionOral7 Eleven2016-05-31Not applicableUs
A.M. Cold Relief FormulaDextromethorphan hydrobromide (15.0 mg) + Acetaminophen (325.0 mg) + Pseudoephedrine hydrochloride (30.0 mg)CapsuleOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Abatuss DmxDextromethorphan hydrobromide (15 mg/5mL) + Dexchlorpheniramine maleate (1 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralKramer Novis.2014-05-25Not applicableUs
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HClDextromethorphan hydrobromide (10 mg/1) + Acetaminophen (325 mg/1) + Doxylamine succinate (6.25 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralCvs Pharmacy,inc2017-07-07Not applicableUs
ACETAMINOPHEN DEXTROMETHORPHAN HYDROBROMIDE and DOXYLAMINE SUCCINATEDextromethorphan hydrobromide (15 mg/1) + Acetaminophen (325 mg/1) + Doxylamine succinate (6.25 mg/1)Capsule, liquid filledOralJ.P. BUSINESS ENTERPRISE2014-12-01Not applicableUs
ACETAMINOPHEN DEXTROMETHORPHAN HYDROBROMIDE and PHENYLEPHRINE HYDROCHLORIDEDextromethorphan hydrobromide (10 mg/1) + Acetaminophen (325 mg/1) + Phenylephrine hydrochloride (5 mg/1)Capsule, liquid filledOralJ.P. BUSINESS ENTERPRISE2014-12-01Not applicableUs
Categories
UNII
7355X3ROTS
CAS number
125-71-3
Weight
Average: 271.404
Monoisotopic: 271.193614429
Chemical Formula
C18H25NO
InChI Key
MKXZASYAUGDDCJ-NJAFHUGGSA-N
InChI
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
IUPAC Name
(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-triene
SMILES
[H][[email protected]]12CC3=C(C=C(OC)C=C3)[[email protected]@]3(CCCC[[email protected]]13[H])CCN2C

Pharmacology

Indication

For treatment and relief of dry cough.

Structured Indications
Pharmacodynamics

Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity.

Mechanism of action

Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan.

TargetActionsOrganism
ASigma non-opioid intracellular receptor 1
agonist
Human
AHCG20471, isoform CRA_c
agonist
Human
AGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
USodium-dependent serotonin transporter
inhibitor
Human
UMembrane-associated progesterone receptor component 1
binder
Human
UNeuronal acetylcholine receptor subunit alpha-3
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-4
antagonist
Human
UNeuronal acetylcholine receptor subunit beta-4
antagonist
Human
UNeuronal acetylcholine receptor subunit beta-2
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-7
antagonist
Human
UMu-type opioid receptor
agonist
Human
UDelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor
agonist
Human
UNADPH oxidase
inhibitor
Human
USodium-dependent noradrenaline transporterNot AvailableHuman
Absorption

Rapidly absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Rapidly and extensively metabolized to dextrorphan (active metabolite). One well known metabolic catalyst involved is a specific cytochrome P450 enzyme known as 2D6, or CYP2D6.

Route of elimination
Not Available
Half life

3-6 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*4(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of dextromethorphan.Details
Cytochrome P450 2D6CYP2D6*6(-;-)T deletion, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of dextromethorphan.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dextromethorphan.Experimental
AbirateroneThe serum concentration of Dextromethorphan can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dextromethorphan.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Dextromethorphan.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dextromethorphan.Approved
AlaproclateAlaproclate may increase the serotonergic activities of Dextromethorphan.Experimental
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dextromethorphan.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dextromethorphan.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Almotriptan.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Dextromethorphan.Approved, Investigational
AmiodaroneThe metabolism of Dextromethorphan can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dextromethorphan.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amperozide.Experimental
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Dextromethorphan.Approved
AprepitantThe serum concentration of Dextromethorphan can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Dextromethorphan can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Dextromethorphan.Approved, Investigational
ArtemetherThe metabolism of Dextromethorphan can be decreased when combined with Artemether.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Asenapine.Approved
AtazanavirThe metabolism of Dextromethorphan can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Dextromethorphan.Approved
AtomoxetineThe metabolism of Dextromethorphan can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Dextromethorphan.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Azaperone.Vet Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Dextromethorphan.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Dextromethorphan.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Benperidol.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
BetaxololThe metabolism of Dextromethorphan can be decreased when combined with Betaxolol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bifeprunox.Investigational
BoceprevirThe metabolism of Dextromethorphan can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Dextromethorphan can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dextromethorphan can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dextromethorphan.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dextromethorphan.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Brexpiprazole.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Dextromethorphan.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bromperidol.Investigational
BupropionThe metabolism of Dextromethorphan can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextromethorphan.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Butaperazine.Experimental
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Dextromethorphan.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dextromethorphan.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Dextromethorphan.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dextromethorphan.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Dextromethorphan.Approved
CapecitabineThe metabolism of Dextromethorphan can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Dextromethorphan can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dextromethorphan.Approved
CariprazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cariprazine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Dextromethorphan.Withdrawn
CelecoxibThe metabolism of Dextromethorphan can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Dextromethorphan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dextromethorphan.Withdrawn
ChloramphenicolThe metabolism of Dextromethorphan can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Dextromethorphan can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Chlorproethazine.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Dextromethorphan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Dextromethorphan.Approved
CinacalcetThe metabolism of Dextromethorphan can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Dextromethorphan.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dextromethorphan.Approved
CitalopramCitalopram may increase the serotonergic activities of Dextromethorphan.Approved
ClarithromycinThe metabolism of Dextromethorphan can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dextromethorphan can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Dextromethorphan.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dextromethorphan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Dextromethorphan.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Dextromethorphan.Approved, Nutraceutical
ClothiapineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Dextromethorphan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Dextromethorphan.Approved
CobicistatThe serum concentration of Dextromethorphan can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dextromethorphan.Approved
CocaineThe metabolism of Dextromethorphan can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dextromethorphan.Approved
ConivaptanThe serum concentration of Dextromethorphan can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Dextromethorphan.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Dextromethorphan.Approved
CrisaboroleThe metabolism of Dextromethorphan can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Dextromethorphan can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Dextromethorphan can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dextromethorphan.Approved
DabrafenibThe serum concentration of Dextromethorphan can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Dextromethorphan.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Dextromethorphan.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dapiprazole.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Dextromethorphan.Investigational
DarifenacinThe metabolism of Dextromethorphan can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Dextromethorphan can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dextromethorphan can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Dextromethorphan.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dextromethorphan.Approved
DeferasiroxThe serum concentration of Dextromethorphan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dextromethorphan can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Desipramine.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Dextromethorphan.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Dextromethorphan.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Dextromethorphan.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dextromethorphan.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Dextromethorphan.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Dextromethorphan.Approved
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dextromethorphan.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dextromethorphan.Illicit
DiltiazemThe metabolism of Dextromethorphan can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Dextromethorphan can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Dextromethorphan.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dixyrazine.Experimental
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dextromethorphan.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Dextromethorphan.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dextromethorphan.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Dextromethorphan can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dextromethorphan.Approved, Investigational
DoxycyclineThe metabolism of Dextromethorphan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Dextromethorphan can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the serotonergic activities of Dextromethorphan.Approved
EcopipamThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dextromethorphan.Approved
EfavirenzThe metabolism of Dextromethorphan can be decreased when combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Dextromethorphan.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dextromethorphan.Approved, Investigational
EliglustatThe metabolism of Dextromethorphan can be decreased when combined with Eliglustat.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Dextromethorphan.Approved
EnzalutamideThe serum concentration of Dextromethorphan can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Dextromethorphan.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Dextromethorphan.Approved, Investigational
ErythromycinThe metabolism of Dextromethorphan can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the serotonergic activities of Dextromethorphan.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Dextromethorphan can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Dextromethorphan can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Dextromethorphan.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Dextromethorphan.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dextromethorphan.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Dextromethorphan.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Dextromethorphan.Approved
EtravirineThe metabolism of Dextromethorphan can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dextromethorphan.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dextromethorphan.Approved
FelodipineThe metabolism of Dextromethorphan can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextromethorphan.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Dextromethorphan.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dextromethorphan.Approved
FloxuridineThe metabolism of Dextromethorphan can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Dextromethorphan can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Dextromethorphan can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the serotonergic activities of Dextromethorphan.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Dextromethorphan.Approved
FluvastatinThe metabolism of Dextromethorphan can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the serotonergic activities of Dextromethorphan.Approved, Investigational
FosamprenavirThe metabolism of Dextromethorphan can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dextromethorphan can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Dextromethorphan can be increased when combined with Fosphenytoin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Dextromethorphan.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dextromethorphan can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Dextromethorphan.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dextromethorphan.Approved
GemfibrozilThe metabolism of Dextromethorphan can be decreased when combined with Gemfibrozil.Approved
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Dextromethorphan.Approved
GranisetronGranisetron may increase the serotonergic activities of Dextromethorphan.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dextromethorphan.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Dextromethorphan.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Dextromethorphan.Approved
HarmalineHarmaline may increase the serotonergic activities of Dextromethorphan.Experimental
HydracarbazineHydracarbazine may increase the serotonergic activities of Dextromethorphan.Experimental
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dextromethorphan.Approved
IdelalisibThe serum concentration of Dextromethorphan can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Iloperidone.Approved
ImatinibThe metabolism of Dextromethorphan can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dextromethorphan.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Dextromethorphan.Approved
IndalpineIndalpine may increase the serotonergic activities of Dextromethorphan.Investigational, Withdrawn
IndinavirThe metabolism of Dextromethorphan can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Dextromethorphan.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dextromethorphan.Approved
IproclozideIproclozide may increase the serotonergic activities of Dextromethorphan.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Dextromethorphan.Withdrawn
IrbesartanThe metabolism of Dextromethorphan can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Dextromethorphan.Approved, Investigational
IsavuconazoniumThe metabolism of Dextromethorphan can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Dextromethorphan.Approved
IsoniazidThe metabolism of Dextromethorphan can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Dextromethorphan can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dextromethorphan can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dextromethorphan can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Dextromethorphan.Approved
KetoconazoleThe metabolism of Dextromethorphan can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dextromethorphan.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dextromethorphan.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Dextromethorphan.Approved, Investigational
LapatinibThe metabolism of Dextromethorphan can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dextromethorphan.Approved
LeflunomideThe metabolism of Dextromethorphan can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dextromethorphan.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Dextromethorphan.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dextromethorphan.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Dextromethorphan.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Dextromethorphan.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Dextromethorphan.Approved
LinezolidThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Linezolid.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lithium.Approved
LobeglitazoneThe metabolism of Dextromethorphan can be decreased when combined with Lobeglitazone.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Dextromethorphan.Approved
LopinavirThe metabolism of Dextromethorphan can be decreased when combined with Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Dextromethorphan.Approved
LovastatinThe metabolism of Dextromethorphan can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Dextromethorphan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dextromethorphan can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Dextromethorphan can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone.Approved
ManidipineThe metabolism of Dextromethorphan can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Dextromethorphan.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Dextromethorphan.Withdrawn
MelperoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Melperone.Approved
MemantineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Memantine.Approved, Investigational
MesoridazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Mesoridazine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dextromethorphan.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dextromethorphan.Approved
MethotrimeprazineThe metabolism of Dextromethorphan can be decreased when combined with Methotrimeprazine.Approved
Methylene blueMethylene blue may increase the serotonergic activities of Dextromethorphan.Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dextromethorphan.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Dextromethorphan.Approved, Illicit
MidostaurinThe metabolism of Dextromethorphan can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Dextromethorphan can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the serotonergic activities of Dextromethorphan.Approved
MinaprineMinaprine may increase the serotonergic activities of Dextromethorphan.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Dextromethorphan.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dextromethorphan.Approved
MitotaneThe serum concentration of Dextromethorphan can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Dextromethorphan.Approved, Investigational
MoclobemideMoclobemide may increase the serotonergic activities of Dextromethorphan.Approved
ModafinilThe metabolism of Dextromethorphan can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Moperone.Experimental
MorphineThe serum concentration of Morphine can be increased when it is combined with Dextromethorphan.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Mosapramine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dextromethorphan.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Dextromethorphan.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dextromethorphan.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Naratriptan.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Dextromethorphan.Approved, Withdrawn
NelfinavirThe metabolism of Dextromethorphan can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dextromethorphan can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dextromethorphan can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Dextromethorphan.Withdrawn
NicardipineThe metabolism of Dextromethorphan can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Dextromethorphan can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Dextromethorphan.Approved
NilotinibThe metabolism of Dextromethorphan can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dextromethorphan.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Dextromethorphan.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Dextromethorphan.Withdrawn
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Dextromethorphan.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Dextromethorphan.Approved, Investigational
OlaparibThe metabolism of Dextromethorphan can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dextromethorphan.Approved
OmeprazoleThe metabolism of Dextromethorphan can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Dextromethorphan.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Dextromethorphan can be increased when it is combined with Osimertinib.Approved
OxypertineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Oxypertine.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
PalbociclibThe serum concentration of Dextromethorphan can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Dextromethorphan.Approved, Investigational
PanobinostatThe serum concentration of Dextromethorphan can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Dextromethorphan can be decreased when combined with Pantoprazole.Approved
ParecoxibThe serum concentration of Dextromethorphan can be increased when it is combined with Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Dextromethorphan.Approved
ParoxetineParoxetine may increase the serotonergic activities of Dextromethorphan.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dextromethorphan.Approved
Peginterferon alfa-2bThe serum concentration of Dextromethorphan can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Penfluridol.Experimental
PentobarbitalThe metabolism of Dextromethorphan can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextromethorphan.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Dextromethorphan.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Dextromethorphan.Withdrawn
PhenobarbitalThe metabolism of Dextromethorphan can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Dextromethorphan.Withdrawn
PhenytoinThe metabolism of Dextromethorphan can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Dextromethorphan.Approved
PimozideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pimozide.Approved
PioglitazoneThe metabolism of Dextromethorphan can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pipotiazine.Approved
PirlindolePirlindole may increase the serotonergic activities of Dextromethorphan.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dextromethorphan.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Dextromethorphan.Withdrawn
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Dextromethorphan.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Dextromethorphan.Approved
PosaconazoleThe metabolism of Dextromethorphan can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dextromethorphan.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Dextromethorphan.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
PrimidoneThe metabolism of Dextromethorphan can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
PromazineThe metabolism of Dextromethorphan can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Promethazine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Propericiazine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Dextromethorphan.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromethorphan.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dextromethorphan.Approved
PyrimethamineThe metabolism of Dextromethorphan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Dextromethorphan can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Dextromethorphan.Approved
QuinidineThe serum concentration of Dextromethorphan can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Dextromethorphan.Approved
RabeprazoleThe metabolism of Dextromethorphan can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Raclopride.Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Dextromethorphan.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dextromethorphan.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Dextromethorphan.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Dextromethorphan.Approved
RifabutinThe metabolism of Dextromethorphan can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dextromethorphan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dextromethorphan can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dextromethorphan.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Dextromethorphan.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ritanserin.Investigational
RitonavirThe metabolism of Dextromethorphan can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Dextromethorphan.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Rizatriptan.Approved
RolapitantThe metabolism of Dextromethorphan can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Dextromethorphan.Approved, Investigational
RopiniroleThe metabolism of Dextromethorphan can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Dextromethorphan can be decreased when combined with Rosiglitazone.Approved, Investigational
SafrazineSafrazine may increase the serotonergic activities of Dextromethorphan.Withdrawn
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Dextromethorphan.Approved, Vet Approved
SaquinavirThe metabolism of Dextromethorphan can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Dextromethorphan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Dextromethorphan.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Dextromethorphan.Approved
SertindoleThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the serotonergic activities of Dextromethorphan.Approved
SildenafilThe metabolism of Dextromethorphan can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dextromethorphan.Approved
SiltuximabThe serum concentration of Dextromethorphan can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dextromethorphan can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Dextromethorphan.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dextromethorphan.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Dextromethorphan.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dextromethorphan.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dextromethorphan.Experimental
St. John's WortThe serum concentration of Dextromethorphan can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dextromethorphan can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Dextromethorphan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Dextromethorphan can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Dextromethorphan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sumatriptan.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Dextromethorphan.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Dextromethorphan.Approved
TapentadolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Dextromethorphan.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dextromethorphan.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Dextromethorphan.Approved
TelaprevirThe metabolism of Dextromethorphan can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Dextromethorphan can be decreased when combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Dextromethorphan.Approved
TerbinafineThe metabolism of Dextromethorphan can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Dextromethorphan can be decreased when combined with Teriflunomide.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tetrahydropalmatine.Investigational
ThiopropazateThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dextromethorphan.Withdrawn
ThiotepaThe metabolism of Dextromethorphan can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Dextromethorphan.Approved
TiclopidineThe metabolism of Dextromethorphan can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Dextromethorphan.Approved
TipranavirThe metabolism of Dextromethorphan can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Dextromethorphan can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Dextromethorphan can be decreased when combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Dextromethorphan.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dextromethorphan.Approved
TopiramateThe metabolism of Dextromethorphan can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Dextromethorphan can be decreased when combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dextromethorphan.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Dextromethorphan.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromethorphan.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dextromethorphan.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Dextromethorphan.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Dextromethorphan.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trazodone.Approved, Investigational
TrifluoperazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe metabolism of Dextromethorphan can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trimipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Dextromethorphan.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dextromethorphan.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dextromethorphan.Approved
Valproic AcidThe metabolism of Dextromethorphan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Dextromethorphan can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dextromethorphan.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Dextromethorphan.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Dextromethorphan.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Dextromethorphan.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Veralipride.Experimental
VerapamilThe metabolism of Dextromethorphan can be decreased when combined with Verapamil.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Dextromethorphan.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dextromethorphan.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Dextromethorphan.Approved
VoriconazoleThe metabolism of Dextromethorphan can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Dextromethorphan.Approved
ZafirlukastThe metabolism of Dextromethorphan can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Dextromethorphan.Approved
ZimelidineZimelidine may increase the serotonergic activities of Dextromethorphan.Withdrawn
ZiprasidoneThe metabolism of Dextromethorphan can be decreased when combined with Ziprasidone.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dextromethorphan.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zotepine.Approved
ZucapsaicinThe metabolism of Dextromethorphan can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Mahendra R. Patel, "Sustained Release Suspension Preparation For Dextromethorphan." U.S. Patent US20130115253, issued May 09, 2013.

US20130115253
General References
  1. Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004 Oct 26;63(8):1364-70. [PubMed:15505150]
  2. Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989 Jun 16;244(4910):1360-2. [PubMed:2660263]
  3. Hargreaves RJ, Hill RG, Iversen LL: Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir Suppl (Wien). 1994;60:15-9. [PubMed:7976530]
  4. Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL: Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. Neurotoxicology. 2007 Jul;28(4):813-8. Epub 2007 Apr 6. [PubMed:17573115]
  5. Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ: Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 2000 Jun;293(3):962-7. [PubMed:10869398]
External Links
KEGG Drug
D03742
KEGG Compound
C06947
PubChem Compound
5360696
PubChem Substance
46506530
ChemSpider
13109865
BindingDB
50366613
ChEBI
92579
ChEMBL
CHEMBL52440
Therapeutic Targets Database
DNC000541
PharmGKB
PA449273
Drugs.com
Drugs.com Drug Page
Wikipedia
Dextromethorphan
ATC Codes
R05DA09 — DextromethorphanN07XX59 — Dextromethorphan, combinations
AHFS Codes
  • 48:08.00 — Antitussives
  • 04:04.04 — Ethanolamine Derivatives
  • 48:16.00 — Expectorants
  • 04:04.00 — First Generation Antihistamines
  • 28:08.92 — Miscellaneous Analgesics and Antipyretics
  • 04:04.12 — Phenothiazine Derivatives
  • 04:04.20 — Propylamine Derivatives
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1CompletedNot AvailableHealthy Adult Volunteers / Pharmacokinetics of Dextromethorphan / Pharmacokinetics of Isavuconazole1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceAlzheimer's Disease (AD) / Huntington's Disease (HD)1
1CompletedBasic ScienceCytomegalovirus (CMV)1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedBasic SciencePharmacokinetics of Caffeine / Pharmacokinetics of Dextromethorphan / Prostate Cancer1
1CompletedDiagnosticDrug Interactions1
1CompletedDiagnosticHealthy Volunteers1
1CompletedDiagnosticSchizophrenic Disorders1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentCognitive Disorders / Healthy Volunteers1
1CompletedTreatmentCoughing / Respiratory Tract Infections (RTI)1
1CompletedTreatmentDrug Interactions1
1CompletedTreatmentExperimental Pain / Hyperalgesia1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentProstate Neoplasms1
1CompletedTreatmentPsoriasis1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentVoice Disorders1
1Not Yet RecruitingTreatmentMajor Depressive Disorder (MDD)1
1RecruitingBasic ScienceHeart Diseases1
1RecruitingBasic ScienceNeoplasms Metastasis1
1RecruitingTreatmentCholangiocarcinomas / Neoplasms, Hepatic1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentTraumas1
1SuspendedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
1TerminatedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood Infratentorial Ependymoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Gonadotroph Adenoma / Pituitary Basophilic Adenoma / Pituitary Chromophobe Adenoma / Pituitary Eosinophilic Adenoma / Prolactin Secreting Adenoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Pituitary Tumor / Recurrent/Refractory Childhood Hodgkin Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / TSH Secreting Adenoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentRecurrent Childhood Anaplastic Astrocytoma / Recurrent Childhood Anaplastic Oligoastrocytoma / Recurrent Childhood Anaplastic Oligodendroglioma / Recurrent Childhood Giant Cell Glioblastoma / Recurrent Childhood Glioblastoma / Recurrent Childhood Gliomatosis Cerebri / Recurrent Childhood Gliosarcoma1
1Unknown StatusTreatmentOpioid-Induced Hyperalgesia1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma3
1, 2CompletedTreatmentDiabetic Macular Edema (DME)1
1, 2Not Yet RecruitingNot AvailableSchizophrenic Disorders1
1, 2RecruitingTreatmentTreatments1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentDe Novo / Low-dose Corticosteroids Pretreatment / Secondary / Untreated Philadelphia Positive Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma2
2CompletedDiagnosticHealthy Volunteers1
2CompletedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedTreatmentAcute Agitation / Alzheimer's Disease (AD)1
2CompletedTreatmentAcute Cerebrovascular Accidents / Edema of the cerebrum1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Hepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAllodynia / Central Neuropathic Pain / Spinal Cord Injuries (SCI)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentCentral Neuropathic Pain / Disseminated Sclerosis1
2CompletedTreatmentContiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Marginal Zone Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDiabetic Neuropathies / Herpes Zoster / Neurocostal neuralgia1
2CompletedTreatmentDyskinesias / Parkinson's Disease (PD)1
2CompletedTreatmentEpisodic Migraine1
2CompletedTreatmentFacial Neuralgia / Pain / Trigeminal Neuralgia (TN)1
2CompletedTreatmentGulf War Illness1
2CompletedTreatmentHypertensive1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentNeurodegenerative Disorders / Parkinson's Disease (PD)1
2CompletedTreatmentOpioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentPain, Neuropathic1
2CompletedTreatmentPrimary Systemic Amyloidosis1
2CompletedTreatmentRett's Syndrome1
2CompletedTreatmentType 2 Diabetes Mellitus1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentChemotherapy-induced Peripheral Neuropathy (CIPN)1
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentMultiple Myeloma (MM)2
2RecruitingTreatmentPlasma Cell Myeloma / Residual Disease1
2TerminatedSupportive CareNausea and Vomiting / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentRecurrent Adult Acute Lymphoblastic Leukemia1
2TerminatedTreatmentRefractory Multiple Myeloma2
2TerminatedTreatmentRett's Syndrome1
2TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentTreatment Refusal1
2Unknown StatusTreatmentAutism, Early Infantile1
2Unknown StatusTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3CompletedTreatmentSchizophrenic Disorders1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3CompletedDiagnosticDevelopment1
3CompletedSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Pain / Precancerous/Nonmalignant Condition / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentBipolar Disorder (BD)1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentLeukemias2
3CompletedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
3CompletedTreatmentMultiple Myeloma (MM)1
3CompletedTreatmentPseudobulbar Affect (PBA)1
3Enrolling by InvitationTreatmentBipolar Disorder II1
3RecruitingTreatmentBilateral Inguinal Hernia / Neurodevelopmental Disorders1
3RecruitingTreatmentMultiple Myeloma (MM)2
3RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3TerminatedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Unknown StatusTreatmentOpioid Abuse1
3Unknown StatusTreatmentProteinuria1
3Unknown StatusTreatmentRett's Syndrome1
4Active Not RecruitingSupportive CareAlzheimer's Disease (AD) / Pseudobulbar Affect (PBA)1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)1
4CompletedBasic ScienceRejection, Transplant1
4CompletedPreventionCognition Disorders / Oxidative Stress1
4CompletedPreventionPreterm Delivery1
4CompletedSupportive CareRobotic Thyroidectomy1
4CompletedTreatmentAtherosclerosis / Inflammatory Reaction / Smoking1
4CompletedTreatmentCough Reflex Sensitivity1
4CompletedTreatmentFailed Moderate Sedation During Procedure / Minimally Conscious State1
4CompletedTreatmentHypothermia1
4CompletedTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma1
4CompletedTreatmentPostoperative pain1
4Not Yet RecruitingSupportive CareColonoscopy1
4Not Yet RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4Not Yet RecruitingTreatmentPostoperative pain1
4Not Yet RecruitingTreatmentSpinal Cord Injuries (SCI)1
4RecruitingBasic ScienceType 2 Diabetes Mellitus1
4RecruitingOtherCYP2D6 Polymorphism1
4RecruitingTreatmentCoughing1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentNeuromuscular Block1
4TerminatedNot AvailablePseudobulbar Affect (Involuntary Laughing and/or Crying)1
4TerminatedTreatmentAcute Rhinitis / Upper Respiratory Tract Infections1
4Unknown StatusPreventionArrythmias / Blood Pressures / Nausea / Pain / Vomiting1
4Unknown StatusTreatmentDementias / Pseudobulbar Affect (PBA) / Strokes / Traumatic Brain Injury (TBI)1
4Unknown StatusTreatmentVitiligo1
4WithdrawnBasic ScienceSickle Cell Disorders1
Not AvailableActive Not RecruitingBasic ScienceHealthy Volunteers1
Not AvailableActive Not RecruitingOtherSleep disorders and disturbances1
Not AvailableActive Not RecruitingPreventionCoronary Artery Bypass, Off-Pump1
Not AvailableActive Not RecruitingSupportive CareAnalgesia Tolerance / Opioid Tolerance / Pain1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableAvailableNot AvailableAttention Deficit Hyperactivity Disorder (ADHD)1
Not AvailableCompletedNot AvailableGrowth Hormone Deficiency, Dwarfism1
Not AvailableCompletedBasic ScienceHypovolaemia / Temperature Change, Body1
Not AvailableCompletedDiagnosticSleep Apnea Syndrome1
Not AvailableCompletedSupportive CareMale Breast Cancer / Nausea and Vomiting / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedSupportive CareNeoplasms, Malignant1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentGeneral Surgery1
Not AvailableCompletedTreatmentRett's Syndrome1
Not AvailableCompletedTreatmentRheumatoid Arthritis1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableRecruitingNot AvailableCerebral Ischemia-Hypoxia1
Not AvailableRecruitingNot AvailableDepressive State1
Not AvailableRecruitingPreventionAcute Kidney Injury (AKI)1
Not AvailableRecruitingPreventionDelirium / Dexmedetomidine / Lower Extremity Problem / Propofol1
Not AvailableRecruitingTreatmentAnaesthesia therapy2
Not AvailableTerminatedNot AvailableCancer, Breast1
Not AvailableTerminatedSupportive CareTiredness / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
Not AvailableTerminatedTreatmentNeurotoxicity Syndromes1
Not AvailableUnknown StatusTreatmentRadiculopathy, Cervical1
Not AvailableWithdrawnSupportive CareIntracranial Pressure Increase1
Not AvailableWithdrawnSupportive CareNeoplasms, Malignant / Ototoxicity1

Pharmacoeconomics

Manufacturers
  • Reckitt benckiser
Packagers
Dosage forms
FormRouteStrength
SuspensionOral30 mg/5mL
SyrupOral20 mg
CapsuleOral15 mg/1
SolutionOral30 mg/10mL
Kit
PowderOral
Tablet, effervescentOral
Granule, effervescentOral
SyrupOral3 mg
SyrupOral30 mg
LozengeOral30 mg
SyrupOral7.5 mg
LozengeOral7.5 mg
StripOral15 mg
Suspension / dropsOral
Solution / dropsOral
LiquidOral12.5 mg
LiquidTopical
LiquidOral
GranuleOral
SolutionOral
Capsule; kitOral
TabletOral
Tablet, coatedOral
Tablet, sugar coatedOral
Suspension, extended releaseOral30 mg/5mL
SyrupOral20 mg/15mL
SyrupOral5 mg/5mL
Kit; powder, for solutionOral
LiquidOral15 mg/15mL
SolutionOral15 mg/15mL
KitOral
SyrupOral30 mg/5mL
Kit
SuspensionOral30 mg
Tablet, chewableOral7.5 mg
SyrupOral15 mg
TabletOral15 mg
CapsuleOral30 mg
SolutionOral7.5 mg
Tablet, orally disintegratingOral30 mg/1
Kit; powderOral
Solution / dropsNasal
Tablet, film coatedOral
StripOral7.5 mg
Tablet, chewableOral
SyrupOral5 mg
Tablet, orally disintegratingOral
Tablet, extended releaseOral
CapsuleOral
Capsule, gelatin coatedOral
StripOral
Capsule, gelatin coatedOral15 mg/1
LiquidOral15 mg
LiquidOral7.5 mg
Capsule, coatedOral
LiquidOral7.5 mg/5mL
PatchTopical
ElixirOral
CapsuleOral15 mg
SyrupOral10 mg
LiquidOral15 mg/5mL
Capsule, liquid filledOral15 mg/1
Capsule, liquid filledOral
LiquidOral10 mg/5mL
LiquidOral30 mg/5mL
LozengeOral
LozengeOral10 mg/1
LozengeOral15 mg
LozengeOral5 mg
LozengeOral10 mg
Powder, for solutionOral
SyrupOral
Kit; tabletOral
SuspensionOral
SyrupOral7.5 mg/5mL
TabletOral7.5 mg
LiquidOral30 mg/10mL
LiquidOral30 mg
Granule, for solutionOral
SprayOral6 mg/.25mL
Prices
Unit descriptionCostUnit
Modicon (28) 28 0.5-35 mg-mcg tablet Disp Pack59.99USD disp
Dextromethorphan powder14.93USD g
Dextromethorphan hbr powder4.74USD g
Dextromethorphan hbr cryst2.06USD g
Triaminic allergy thin strip0.35USD strip
Triaminic cold-stuff nose strip0.35USD strip
Triaminic cgh-runny nose strip0.3USD each
Triaminic cough strips0.3USD strip
Triaminic cough-cold chew0.27USD each
Triaminic softchew tablet0.27USD tablet
Robitussin coughgels0.25USD each
Triaminic softchews tablet0.25USD tablet
Childrens triaminic decon spray0.24USD ml
Hold 4 hour lozenge regular0.24USD lozenge
Hca severe cough stopper cplet0.23USD each
Triaminicin tablet0.23USD tablet
Delsym 30 mg/5 ml suspension0.11USD ml
Robitussin dm to go liquid0.09USD ml
Apap allergy sinus caplet0.05USD caplet
Adlt robitussin cough-cold-flu0.04USD ml
Adt robitussin cough-cold d lq0.04USD ml
Adult robitussin cough syrup0.04USD ml
Robitussin chest congest syrup0.04USD ml
Robitussin cough & cold liquid0.04USD ml
Robitussin cough-cold liquid0.04USD ml
Robitussin cough-cong syrup0.04USD ml
Robitussin dm max liquid0.04USD ml
Robitussin long-acting liq0.04USD ml
Robitussin pe head & chest liq0.04USD ml
Robitussin-cough-chest-cong lq0.04USD ml
Robitussin-dm cough syrup0.04USD ml
Triaminic chest-nasal cong liq0.04USD ml
Triaminic cold & cough liquid0.04USD ml
Triaminic cold-allergy pe liq0.04USD ml
Triaminic cough-nasal cong liq0.04USD ml
Triaminic cough-sore throat lq0.04USD ml
Triaminic flu cough-fever susp0.04USD ml
Triaminic flu-cough-fever liq0.04USD ml
Triaminic-d syrup0.04USD ml
Vicks 44 cough liquid0.03USD ml
Vicks 44 custom care liquid0.03USD ml
Guaifenesin dm syrup0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5980882No1997-04-162017-04-16Us
US6372252No2000-04-282020-04-28Us
US6955821No2000-04-282020-04-28Us
US7838032No2000-04-282020-04-28Us
US7659282No2006-08-132026-08-13Us
US8227484No2003-07-172023-07-17Us
USRE38115No1996-01-262016-01-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)122-124Schnider, O. and Grussner, A,; US. Patent 2,676,177; April 20, 1954; assigned to Hoffrnann-La Roche Inc.
water solubility74.7 mg/LNot Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00851 mg/mLALOGPS
logP3.75ALOGPS
logP3.49ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)9.85ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.56 m3·mol-1ChemAxon
Polarizability31.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9989
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8288
P-glycoprotein inhibitor IInhibitor0.654
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.7893
CYP450 2C9 substrateNon-substrate0.8187
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7783
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8673
Ames testNon AMES toxic0.5664
CarcinogenicityNon-carcinogens0.9616
BiodegradationNot ready biodegradable0.9763
Rat acute toxicity3.3377 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7107
hERG inhibition (predictor II)Inhibitor0.6723
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Mass Spectrum (Electron Ionization)MSsplash10-00di-5890000000-3009baa7e8a19f9be270
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0190000000-df99af2429c385c2ac44
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-1a3ed289b3e93cd6fde4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-ebc22884ca50d755e2e4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-63612671cfd5e7808f7e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-02mi-0490000000-10cc5d461942becb6194
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-022a-0930000000-943342d8d5a3ae45227f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-eb4c5442e33e6921c728
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-a39a4c295bd6e3b25181
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-5191ea197708a687222f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-3d90a3bd5c1b6788ed43
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-02mi-0490000000-ddc598f28e1a4f9008d1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-022a-0940000000-cbb4007ab43d33441b69
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-457827e6b58fa1a77623
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0190000000-23c81d81c3ea162f7ab7

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Benzazocines / Tetralins / Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Morphinan / Phenanthrene / Benzazocine / Tetralin / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Benzenoid / Tertiary aliphatic amine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma m...
Gene Name
SIGMAR1
Uniprot ID
Q99720
Uniprot Name
Sigma non-opioid intracellular receptor 1
Molecular Weight
25127.52 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP, Baek IH, Kim WK, Maurice T, Nabeshima T, Kim HC: Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem Int. 2007 May;50(6):791-9. Epub 2007 Feb 4. [PubMed:17386960]
  4. Shin EJ, Nah SY, Kim WK, Ko KH, Jhoo WK, Lim YK, Cha JY, Chen CF, Kim HC: The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan. Br J Pharmacol. 2005 Apr;144(7):908-18. [PubMed:15723099]
  5. Church AJ, Andrew RD: Spreading depression expands traumatic injury in neocortical brain slices. J Neurotrauma. 2005 Feb;22(2):277-90. [PubMed:15716633]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Not Available
Specific Function
Not Available
Gene Name
SIGMAR1
Uniprot ID
Q5T1J1
Uniprot Name
HCG20471, isoform CRA_c
Molecular Weight
14852.655 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chou YC, Liao JF, Chang WY, Lin MF, Chen CF: Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999 Mar 13;821(2):516-9. [PubMed:10064839]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chou YC, Liao JF, Chang WY, Lin MF, Chen CF: Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999 Mar 13;821(2):516-9. [PubMed:10064839]
  4. Wong BY, Coulter DA, Choi DW, Prince DA: Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett. 1988 Feb 29;85(2):261-6. [PubMed:2897648]
  5. Kamel IR, Wendling WW, Chen D, Wendling KS, Harakal C, Carlsson C: N-methyl-D-aspartate (NMDA) antagonists--S(+)-ketamine, dextrorphan, and dextromethorphan--act as calcium antagonists on bovine cerebral arteries. J Neurosurg Anesthesiol. 2008 Oct;20(4):241-8. doi: 10.1097/ANA.0b013e31817f523f. [PubMed:18812887]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Damaj MI, Flood P, Ho KK, May EL, Martin BR: Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2005 Feb;312(2):780-5. Epub 2004 Sep 8. [PubMed:15356218]
  4. Lee JH, Shin EJ, Jeong SM, Kim JH, Lee BH, Yoon IS, Lee JH, Choi SH, Lee SM, Lee PH, Kim HC, Nah SY: Effects of dextrorotatory morphinans on alpha3beta4 nicotinic acetylcholine receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2006 Apr 24;536(1-2):85-92. Epub 2006 Mar 2. [PubMed:16563374]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70. [PubMed:7562497]
  4. Henderson MG, Fuller RW: Dextromethorphan antagonizes the acute depletion of brain serotonin by p-chloroamphetamine and H75/12 in rats. Brain Res. 1992 Oct 30;594(2):323-6. [PubMed:1280529]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Receptor for progesterone.
Gene Name
PGRMC1
Uniprot ID
O00264
Uniprot Name
Membrane-associated progesterone receptor component 1
Molecular Weight
21670.9 Da
References
  1. Chou YC, Liao JF, Chang WY, Lin MF, Chen CF: Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999 Mar 13;821(2):516-9. [PubMed:10064839]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA3
Uniprot ID
P32297
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-3
Molecular Weight
57479.54 Da
References
  1. Damaj MI, Flood P, Ho KK, May EL, Martin BR: Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2005 Feb;312(2):780-5. Epub 2004 Sep 8. [PubMed:15356218]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Damaj MI, Flood P, Ho KK, May EL, Martin BR: Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2005 Feb;312(2):780-5. Epub 2004 Sep 8. [PubMed:15356218]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB4
Uniprot ID
P30926
Uniprot Name
Neuronal acetylcholine receptor subunit beta-4
Molecular Weight
56378.985 Da
References
  1. Damaj MI, Flood P, Ho KK, May EL, Martin BR: Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2005 Feb;312(2):780-5. Epub 2004 Sep 8. [PubMed:15356218]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Damaj MI, Flood P, Ho KK, May EL, Martin BR: Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2005 Feb;312(2):780-5. Epub 2004 Sep 8. [PubMed:15356218]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Damaj MI, Flood P, Ho KK, May EL, Martin BR: Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2005 Feb;312(2):780-5. Epub 2004 Sep 8. [PubMed:15356218]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70. [PubMed:7562497]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70. [PubMed:7562497]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70. [PubMed:7562497]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated ion channel activity
Specific Function
Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. It is the terminal component of a respiratory chain that transfers single electrons from cytoplasmic NADPH ...
Gene Name
CYBB
Uniprot ID
P04839
Uniprot Name
Cytochrome b-245 heavy chain
Molecular Weight
65335.415 Da
References
  1. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Zhang W, Hong JS, Liu B: Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J. 2004 Mar;18(3):589-91. Epub 2004 Jan 20. [PubMed:14734632]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70. [PubMed:7562497]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Yu A, Haining RL: Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20. [PubMed:11602530]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. [PubMed:19817501]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Zhang T, Zhu Y, Gunaratna C: Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):371-9. [PubMed:12401364]
  5. Yu A, Haining RL: Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20. [PubMed:11602530]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  7. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Yu A, Haining RL: Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20. [PubMed:11602530]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603. [PubMed:11743742]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:16